Dominari Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Dominari Holdings şirketinin toplam hissedar öz sermayesi $38.3M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $43.4M ve $5.2M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$7.17m
Eşitlik	US$38.27m
Toplam yükümlülükler	US$5.16m
Toplam varlıklar	US$43.43m

Son finansal sağlık güncellemeleri

AIkido Pharma (NASDAQ:AIKI) Is In A Good Position To Deliver On Growth Plans

May 04

AIkido Pharma (NASDAQ:AIKI) Is In A Good Position To Deliver On Growth Plans

Jan 14

Here's Why We're Not Too Worried About AIkido Pharma's (NASDAQ:AIKI) Cash Burn Situation

Sep 29

We Think AIkido Pharma (NASDAQ:AIKI) Can Easily Afford To Drive Business Growth

Jun 05

Recent updates

Here's Why We're Not Too Worried About AIkido Pharma's (NASDAQ:AIKI) Cash Burn Situation

Sep 29

We Think AIkido Pharma (NASDAQ:AIKI) Can Easily Afford To Drive Business Growth

Jun 05

AIkido Pharma's stock surges on psilocybin patent license agreement

Jan 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: DOMH 'nin kısa vadeli varlıkları ( $24.8M ) kısa vadeli yükümlülüklerini ( $2.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: DOMH şirketinin kısa vadeli varlıkları ( $24.8M ) uzun vadeli yükümlülüklerini ( $2.7M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: DOMH borçsuzdur.

Borcun Azaltılması: DOMH son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: DOMH şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: DOMH un, serbest nakit akışı her yıl % 36 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Dominari Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

AIkido Pharma Regains Compliance with NASDAQ Listing Requirements

AIkido Pharma (NASDAQ:AIKI) Is In A Good Position To Deliver On Growth Plans

AIkido Pharma (NASDAQ:AIKI) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About AIkido Pharma's (NASDAQ:AIKI) Cash Burn Situation

We Think AIkido Pharma (NASDAQ:AIKI) Can Easily Afford To Drive Business Growth

AIkido Pharma Regains Compliance with NASDAQ Minimum Bid Price Listing Requirements

Recent updates

New major risk - Market cap size

Third quarter 2024 earnings released: US$0.67 loss per share (vs US$0.66 loss in 3Q 2023)

Dominari Holdings Inc., Annual General Meeting, Nov 06, 2024

New minor risk - Share price stability

CEO & Chairman recently bought US$140k worth of stock

Dominari Holdings Inc. Announces Appointment of Mr. Kyle Wool as President

New minor risk - Shareholder dilution

Dominari Holdings Inc. Announces Executive Changes

New major risk - Market cap size

Dominari Holdings Inc. Announces Resignation of Paul Lemire as Member of the Board of Directors and Member of Audit Committee, Compensation Committee, and Nominating Committee

Dominari Holdings Inc. Announces Management Changes

New minor risk - Shareholder dilution

Dominari Holdings Inc., Annual General Meeting, Sep 21, 2023

New major risk - Financial position

Dominari Holdings Inc. Appoints Kyle Wool as CEO of Dominari Securities LLC

Dominari Holdings Inc. Appoints Matthew B. McCullough as the General Counsel

CEO, Principal Financial Officer recently bought US$103k worth of stock

Dominari Holdings Inc. Appoints Christopher Devall as Chief Operating Officer

AIkido Pharma Inc.(NasdaqCM:DOMH) dropped from NASDAQ Composite Index

AIkido Pharma Inc. (NasdaqCM:AIKI) announces an Equity Buyback for $2 million worth of its shares.

Price target decreased to US$16.00

High number of new directors

AIkido continues to buyback more shares

AIkido Pharma's subsidiary agrees to buy broker-dealer firm

Shalom Auerbach made an offer to acquire additional 96.2% stake in AIkido Pharma Inc. (NasdaqCM:AIKI) for $40.4 million.

Alkido Pharma shareholders proposes to acquire company at $8/share in cash

High number of new directors

AIkido Pharma Regains Compliance with NASDAQ Listing Requirements

AIkido Pharma Inc. Appoints Soo Yu as Director

Shalom Auerbach Issues an Open Letter to Board of Directors of AIkido Pharma

AIkido Pharma Inc. (NasdaqCM:AIKI) acquired an unknown stake in Databricks, Inc.

AIkido Pharma (NASDAQ:AIKI) Is In A Good Position To Deliver On Growth Plans

High number of new and inexperienced directors

AIkido Pharma Inc., Annual General Meeting, May 16, 2022

AIkido Pharma Inc. Reports Improved Manufacturing Process and New United States Patent for Pancreatic Drug

AIkido Pharma: Advancing Anticancer And Antiviral Therapies

AIkido Pharma Inc. (NasdaqCM:AIKI) announces an Equity Buyback for $3 million worth of its shares.

AIkido Pharma (NASDAQ:AIKI) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About AIkido Pharma's (NASDAQ:AIKI) Cash Burn Situation

Aikido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer's Disease

We Think AIkido Pharma (NASDAQ:AIKI) Can Easily Afford To Drive Business Growth

AIkido Pharma Inc. Announces Phase 1 Data to Be Presented at the American Society of Clinical Oncology Annual Meeting

Aikido Pharma Provides Update on Its Antiviral Platform, Including the Virus That Causes COVID-19

New 90-day high: US$1.91

Aikido Pharma Inc. Appoints Scott T. Tagawa, M.D. to Scientific Advisory Board

AIkido Pharma Inc. Appoints Neil H. Bander as Company's Scientific Advisory Board

New 90-day high: US$1.21

AIkido Pharma Inc. Executes Licensing Agreement for Psilocybin for Cancer Applications

AIkido Pharma's stock surges on psilocybin patent license agreement

New 90-day high: US$0.73

AIkido Pharma Inc. Announces Publication of Artificial Intelligence-Machine Learning Sponsored Research Program for Pancreatic Cancer

New 90-day high: US$0.67

Aikido Pharma Inc. Announces Publication of Positive Results from A Study of Antiviral Activity of FDA Approved Drugs

New 90-day low: US$0.54

New 90-day low: US$0.55

New 90-day high - US$1.23

Earnings released

AIkido Pharma Regains Compliance with NASDAQ Minimum Bid Price Listing Requirements

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin